Patients with hemin prophylaxis (%) 46.4% SEM, Standard error of the mean* Patients were asked at baseline about their healthcare utilization in past 12 months; ** Total hospitalization days is approximated by product of number of times the patient stayed overnight in the hospital in past 12 months and average duration of hospital stay up to 4 hospitalization for that patient
• Healthcare utilization and expenditures for management of patients with AHP was high, driven by hospitalizations and hemin use, both for attacks and prophylactically • Estimated average annual expenditure/patient was $398, 463 (95% CI: $328, 477) to $655,418 (95% CI: $482,278 -$847,448) depending on whether hospital costs or charges were used • Limitations included:
-Annual expenditure/patient is presented as both hospital cost and charge; charge may overestimate annual expenditure/patient and cost may underestimate annual expenditure/ patient -ICD-9 code is not specific to porphyrias; thus hospitalization costs may be under-represented due to disease severity; both costs and charges are presented -Indirect costs and other treatment costs (e.g., treating disease complications and adverse events) were not captured -Variability of patient's clinical presentation results in differences in costs and utilization, thus a PSA was conducted to account for uncertainty around sample mean -Use of hemin was based on one expert's opinion and future studies should look at actual use of hemin
• Treatment options that reduce attacks and thereby hospitalizations may result in lower economic burden on US health care system • This is the first study to estimate expenditures associated with management of AHP and represents a significant burden to US healthcare system; future studies should evaluate expenditures from claims databases and expenditures associated with management of AHP in other countries PCP, Primary Care Physician; ER, emergency room *Categorical data for PCP and specialist office visits were converted to mean annual visits by multiplying the frequency of response by the number of annual visits (e.g., monthly visits were represented as 12 annual visits) and the average for the entire sample was estimated.
Hemin prophylaxis utilization at baseline was also converted from categorical response to mean annual infusions per patient by multiplying the frequency of response by the number of annual infusions for the entire response set. Treatment days with hemin per attack were based on expert opinion from Dr Balwani, who reports that the average attack is treated for 4 days. It was assumed that 50% of prophylaxis patients receive their infusions in the office. For acute attacks, it was estimated that 69% of AHP patients and 70% of AIP patients receive infusions in the office (based on the ratio of attacks treated in a health care facility to all on-study attacks 
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Results
Summary
Methods
• Healthcare resource utilization data from EXPLORE ( Figure 2 ) and unit costs of resources (charges and economic costs) from publicly available sources (Table 1) were used to estimate annual expenditure per patient ( Figure 3) ; both hospital charges (amount billed) and costs (amount paid) were reported. This analysis does not include indirect costs such as cost due to missed days of work, and caregiver costs.
• EXPLORE analysis included data for hospitalizations (including length of stay), ER visits, and GP/Specialist visits -Patients asked at baseline about healthcare utilization over past 12 months
• Frequency of hemin prophylaxis use was filled out by health care provider and obtained from current medication log • Attack rate and duration during study period calculated -Use of hemin to manage attacks estimated based on expert opinion depending on duration of attack
• Probabilistic sensitivity analysis (PSA) conducted to quantify uncertainty in model estimates -Uncertainty in annual resource utilization inputs obtained from EXPLORE was quantified in terms of mean and standard errors -Standard errors calculated from reported standard deviation and study sample size or otherwise calculated from data
Patient and Disease Characteristics
• 112 patients (mean 39.3 years, 89% female, 85% white/Caucasian) enrolled from 13 countries (US: 44%; EU (12 countries): 56%) -AHP subtype: 93% AIP, 3% HCP, and 4% VP -Follow-up: 107 (96%) and 80 (71%) patients completed 6 and 12 months, respectively
• Commonly associated medical conditions included renal/vascular disorders (38%), nervous system disorders (31%), psychiatric/sleep disorders (30%), and gastrointestinal disorders (22%) • Patients reported annualized attack rate of 4.9 with average duration of 7 days. Patients with hemin prophylaxis had annualized attack rate of 4.1 and those without prophylaxis had an attack rate of 5.5
Healthcare Utilization Rates • Patients reported frequent health care utilization use with an average of 4.5 hospitalizations lasting an average of 6.6 days ( 
Costs
• Overall expenditures associated with management of AHP are high, with the greatest costs associated with hospitalizations and hemin use both for management of attacks as well as prophylaxis use (Table 3) -Average annual expenditure based on hospital cost estimates per patient is about $398,463 ($328,303 -$475,477) 
